259 related articles for article (PubMed ID: 26173973)
1. How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia.
Macaluso M; Kazanchi H; Preskorn SH
Expert Opin Drug Metab Toxicol; 2015; 11(8):1317-27. PubMed ID: 26173973
[TBL] [Abstract][Full Text] [Related]
2. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders.
Pompili M; Verzura C; Trovini G; Buscajoni A; Falcone G; Naim S; Nardella A; Sorice S; Baldessarini RJ; Girardi P
Expert Opin Drug Saf; 2018 Feb; 17(2):197-205. PubMed ID: 28902525
[TBL] [Abstract][Full Text] [Related]
3. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile.
Jaeschke RR; Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Styczeń K; Datka W
Pharmacol Rep; 2016 Aug; 68(4):748-55. PubMed ID: 27203278
[TBL] [Abstract][Full Text] [Related]
4. Lurasidone in the treatment of schizophrenia: a critical evaluation.
Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
[TBL] [Abstract][Full Text] [Related]
5. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Samalin L; Honciuc M; Llorca PM
Encephale; 2015 Dec; 41(6):541-9. PubMed ID: 26603973
[TBL] [Abstract][Full Text] [Related]
6. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
[TBL] [Abstract][Full Text] [Related]
7. Lurasidone for schizophrenia.
Drug Ther Bull; 2015 Mar; 53(3):30-2. PubMed ID: 25765597
[TBL] [Abstract][Full Text] [Related]
8. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
[TBL] [Abstract][Full Text] [Related]
9. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.
Jena M; Mishra A; Mishra BR; Nath S; Maiti R
Psychopharmacology (Berl); 2020 Nov; 237(11):3471-3480. PubMed ID: 32740676
[TBL] [Abstract][Full Text] [Related]
10. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
[TBL] [Abstract][Full Text] [Related]
11. Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice.
Fiorillo A; Cuomo A; Sampogna G; Albert U; Calò P; Cerveri G; De Filippis S; Masi G; Pompili M; Serafini G; Vita A; Zuddas A; Fagiolini A
Expert Opin Pharmacother; 2022 Nov; 23(16):1801-1818. PubMed ID: 36398838
[TBL] [Abstract][Full Text] [Related]
12. Lurasidone: an antipsychotic with antidepressant effects in bipolar depression?
Keks NA; Hope J; Castle D
Australas Psychiatry; 2016 Jun; 24(3):289-91. PubMed ID: 27036122
[TBL] [Abstract][Full Text] [Related]
13. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study.
Harvey PD; Siu CO; Ogasa M; Loebel A
Schizophr Res; 2015 Aug; 166(1-3):334-8. PubMed ID: 26117157
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic lurasidone: Behavioural and pharmacokinetic data in C57BL/6 mice.
Percelay S; Since M; Lagadu S; Freret T; Bouet V; Boulouard M
Pharmacol Biochem Behav; 2020 Jul; 194():172933. PubMed ID: 32371059
[TBL] [Abstract][Full Text] [Related]
15. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation.
Loebel A; Citrome L; Correll CU; Xu J; Cucchiaro J; Kane JM
BMC Psychiatry; 2015 Oct; 15():271. PubMed ID: 26521019
[TBL] [Abstract][Full Text] [Related]
16. Lurasidone: a new treatment option for schizophrenia.
Owen RT
Drugs Today (Barc); 2011 Nov; 47(11):807-16. PubMed ID: 22146224
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study.
Higuchi T; Ishigooka J; Iyo M; Hagi K
Asia Pac Psychiatry; 2020 Mar; 12(1):e12377. PubMed ID: 31837113
[TBL] [Abstract][Full Text] [Related]
18. Lurasidone in schizophrenia: new information about dosage and place in therapy.
Citrome L
Adv Ther; 2012 Oct; 29(10):815-25. PubMed ID: 23001538
[TBL] [Abstract][Full Text] [Related]
19. Lurasidone : in the treatment of schizophrenia.
Sanford M
CNS Drugs; 2013 Jan; 27(1):67-80. PubMed ID: 23264146
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.
Miura I; Horikoshi S; Ichinose M; Suzuki Y; Watanabe K
Drug Des Devel Ther; 2023; 17():3023-3031. PubMed ID: 37789971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
